The poor prognosis associated with TP53 mutant AML reflects not only the loss of canonical tumor suppressor function but also the unique genomic instability, clonal dynamics, and microenvironmental interactions that accompany TP53 gene dysfunction. This evidence concerns the gene TP53 and acute myeloid leukemia.